FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. [electronic resource]
Producer: 20100408Description: 2085-94 p. digitalISSN:- 1538-7445
- Antineoplastic Agents, Hormonal -- pharmacology
- Breast Neoplasms -- drug therapy
- Cell Adhesion -- genetics
- Cell Growth Processes -- genetics
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Estradiol -- analogs & derivatives
- Female
- Fibroblast Growth Factor 2 -- pharmacology
- Fulvestrant
- Gene Amplification
- Gene Silencing
- Humans
- MAP Kinase Signaling System
- Mitogen-Activated Protein Kinase 1 -- metabolism
- Mitogen-Activated Protein Kinase 3 -- metabolism
- Phosphatidylinositol 3-Kinases -- metabolism
- Phosphorylation
- RNA, Messenger -- biosynthesis
- Receptor, Fibroblast Growth Factor, Type 1 -- biosynthesis
- Receptors, Estrogen -- biosynthesis
- Tamoxifen -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.